Thalassemia Specialist Moradabad

Thalassemia Specialist in Moradabad — Expert Diagnosis, Management & Bone Marrow Transplant Care at Jigyasa Hospital

For parents of a child diagnosed with thalassemia, the moment of diagnosis changes everything. Suddenly there are questions about blood transfusions, iron overload, bone marrow donors, and what kind of future their child may have. For families in Moradabad, Rampur, Bareilly, Bijnor, Sambhal, and across western Uttar Pradesh, finding this kind of specialist care locally has historically been difficult.

Jigyasa Hospital, Moradabad is changing that. Dr. Faran Naim brings dedicated subspecialty care in Hematology and Bone Marrow Transplant to families dealing with thalassemia, making advanced guidance available much closer to home.

From first diagnosis and carrier screening to transfusion planning, iron chelation, organ monitoring, transplant evaluation, and curative counselling, families across the Rohilkhand region can now access expert thalassemia care at Jigyasa Hospital.

What Is Thalassemia?

Thalassemia is an inherited blood disorder caused by mutations in the genes responsible for producing haemoglobin, the protein inside red blood cells that carries oxygen throughout the body. When haemoglobin production is defective, red blood cells become fragile, abnormally shaped, and short-lived, leading to chronic and often severe anaemia.

The disorder is passed from parents to children through genes. If both parents carry the thalassemia trait, each pregnancy carries a 25% chance of resulting in a child with thalassemia major. If only one parent is a carrier, children may inherit the trait but usually do not develop thalassemia major.

This is why carrier screening before marriage or pregnancy, and proper genetic counselling by a specialist, are among the most powerful ways to reduce the burden of thalassemia major in communities where the trait is common.

Types of Thalassemia

Beta-thalassemia major, also known as Cooley's anaemia, is the most severe and clinically significant form. Children often appear normal at birth but develop severe anaemia within the first few months of life as the body switches from foetal to adult haemoglobin. Without treatment, it is life-threatening, while long-term survival depends on regular transfusions and proper iron chelation.

Beta-thalassemia intermedia is less severe than major but more significant than the trait. Some patients do not need regular transfusions early in life but may later become transfusion dependent. Beta-thalassemia trait, or minor, usually causes no serious illness but is extremely important from a family planning and genetic risk perspective.

Alpha-thalassemia results from mutations in the alpha-globin genes and ranges from mild carrier states to severe fetal disease. Another important form is HbE/beta-thalassemia, where a beta-thalassemia gene and an HbE gene are inherited together, producing a condition that may behave like thalassemia intermedia or thalassemia major.

Because each type behaves differently, accurate classification is essential before deciding on transfusions, chelation, genetic counselling, or bone marrow transplant planning.

Diagnosis of Thalassemia at Jigyasa Hospital

Accurate diagnosis is the foundation of thalassemia management. Dr. Faran Naim follows a structured diagnostic approach starting with Complete Blood Count and red cell indices, which often show low haemoglobin, low MCV, and low MCH. This pattern can look similar to iron deficiency, which is why expert interpretation matters before iron is prescribed.

High-Performance Liquid Chromatography, or HPLC, is the key test used to identify and quantify different haemoglobin fractions such as HbA, HbA2, HbF, HbS, and HbE. It helps classify the specific thalassemia type and often confirms carrier state or major disease with much greater accuracy than routine blood tests alone.

Molecular genetic testing may be used to identify the exact gene mutation, especially when planning family counselling or bone marrow transplant evaluation. Parental screening and wider family screening are also important whenever a child is diagnosed.

In patients who need long-term transfusions, ferritin and iron studies are monitored regularly. Organ-function assessment of the heart, liver, and endocrine system is also essential to detect complications of iron overload early and manage them in a timely way.

Management of Thalassemia at Jigyasa Hospital

Dr. Faran Naim provides comprehensive thalassemia management tailored to each patient's age, severity, transfusion needs, organ status, and family circumstances. For thalassemia major, regular blood transfusions every 2 to 4 weeks are the cornerstone of supportive care and help maintain haemoglobin at levels that support growth, development, and daily function.

Because each transfusion adds iron to the body, iron chelation is a critical part of long-term care. Depending on age, ferritin, cardiac risk, kidney and liver function, and treatment tolerance, Dr. Naim may use deferoxamine, deferasirox, deferiprone, or combination strategies with regular monitoring.

In selected cases, splenectomy may reduce transfusion burden when hypersplenism develops, but this decision requires careful evaluation because removal of the spleen also increases lifetime infection risk. Endocrine, cardiac, liver, and bone complications are monitored and managed continuously in patients on long-term transfusion support.

The goal is not only to keep haemoglobin adequate, but also to protect the heart, liver, pancreas, hormone systems, growth, and long-term quality of life through systematic specialist care.

Bone Marrow Transplant — The Only Cure for Thalassemia Major

Allogeneic stem cell transplantation, also called bone marrow transplant, is currently the only curative treatment for thalassemia major. It replaces the patient's defective marrow with healthy donor stem cells that can produce normal haemoglobin, freeing the patient from lifelong transfusions and preventing ongoing iron accumulation.

The best candidates are usually children with transfusion-dependent thalassemia major who are younger, have good heart and liver function, and ideally have a matched sibling donor. Outcomes are most favorable when transplant planning begins early, before years of iron overload and organ damage complicate the process.

When a matched sibling donor is not available, matched unrelated donor or haploidentical transplant pathways may still be considered in selected situations. These decisions depend on donor availability, disease burden, organ status, and the overall transplant strategy.

Dr. Faran Naim helps families begin this evaluation early, including HLA typing, risk assessment, counselling, and planning for the most appropriate curative pathway.

Why Choose Dr. Faran Naim and Jigyasa Hospital?

Thalassemia needs a hematologist, not just general supportive treatment. Dr. Faran Naim's specialist expertise in Hematology and Bone Marrow Transplant allows him to guide the full thalassemia journey, from first diagnosis and family counselling to transfusion protocols, iron chelation, organ monitoring, and curative transplant evaluation.

Jigyasa Hospital provides coordinated care under one roof, including diagnostic workup, transfusion support, ferritin and organ monitoring, splenectomy decision support, and BMT-related assessment. This continuity is especially valuable for families who otherwise would need repeated travel to metro cities.

Dr. Naim's work also extends beyond treatment to prevention. Carrier screening, parental testing, and genetic counselling help families understand risk clearly and reduce the future burden of thalassemia major in western Uttar Pradesh.

For children who need lifelong monthly transfusions and regular specialist review, having expert care in Moradabad means fewer delays, less disruption, and more consistent long-term outcomes.

Patient Experiences

Frequently Asked Questions — Thalassemia Specialist in Moradabad